荷丹片对非糖尿病代谢综合征患者胰岛素抵抗、血脂及炎症因子的影响

Effects of Hedan tablet on IR,blood lipid and inflammatory factor in nondiabetic patients with the metabolic syndrome

目的探讨荷丹片对非糖尿病代谢综合征患者胰岛素抵抗、血脂及炎症因子的影响。方法采用随机对照的方法,将98例非糖尿病代谢综合征患者分为2组,分别给予荷丹片和罗格列酮治疗12周,观察2组治疗后WC、BMI、FPG、FINS、HOMA-IR、TG、TC、HDL-C、LDL-C、CRP、TNF-α、FIB的变化。结果2组治疗后FINS、HOMA-IR、CRP、FIB水平均降低,且组间比较无显著性差异;荷丹片组治疗后WC、BMI、TC、TG明显下降,HDL-C明显升高,且较罗格列酮组更显著。结论荷丹片可有效改善非糖尿病代谢综合征患者血脂水平,减轻胰岛素抵抗、肥胖和炎症状态。

Objective It is to observe the influence of Hedan tablet on IR, blood lipid and inflammatory factor in nondia- betic patients with the metabolic syndrome. Methods 98 nondiabetic patients with the metabolic syndrome were randomly divided into Hedan tablet treatment and Rosiglitazone treatment groups, with 49 cases in each. After 12 week＇s treatment, the levels of WC, BMI, FBG, FINS, HOMA- IR, TG, TC, HDL- C, LDL- C, CRP, TNF- α and FIB before and after treatment in both groups were compared. Results The levels of FINS, HOMA- IR, CRP and FIB in both groups were decreased after treatment. Compared with Rosiglitazone treatment group, the levels of WC, BMI, TC and TG were decreased obviously as well as the level of HDL- C were increased significantly after treatment with Hedano tablet（P〈0.05）. Conclusion Hedan tablet can significantly decrease the levels of blood lipid, alleviate IR, fat and inflammatory states.